ENGN Stock — enGene Therapeutics Inc.: Cash, EV, Pipeline

Share price

$1.91

Market cap

$128.0M

Cash

$258.5M

Enterprise value

-$130.5M

Balance sheet

Cash	$258.5M
Debt	$0.0M
Net cash	$258.5M
Enterprise value	-$130.5M
Basic shares	67.0M shares
Fully diluted shares	95.9M shares
Fully diluted market cap	$183.3M
Cash per share	$3.86

Cash figures as of 2026-04-30. Database snapshot: 2026-09-21.

Price history

Loading ENGN daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jun 11 - Jul 23	EG-70 (phase 1)	Phase 1/2	Superficial Bladder Cancer; Non-muscle Invasive Bladder Cancer With Carcinoma in Situ; Non-muscle Invasive Bladder Cancer	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

detalimogene

Phase 2 · Active Modality: genetic medicine (DDX non-viral gene delivery platform); dual RIG-I agonist

Aliases EG-70, detalimogene voraplasmid

Target RIG-I

Partnerships Nature Technology Corporation: non-exclusive Nanoplasmid license (Apr 2020). Company retains all development and commercialization rights to detalimogene

Indications

High-risk BCG-unresponsive NMIBC with CIS (pivotal) (Phase 2)
BCG-naive NMIBC with CIS (Phase 2)
BCG-exposed NMIBC with CIS (Phase 2)
BCG-unresponsive papillary-only NMIBC (no CIS) (Phase 2)

Catalysts

— Q4 2026

Status note Lead product candidate. LEGEND (NCT04752722): combined Phase 1/2 open-label; Cohort 1 pivotal enrolled 125 patients with high-risk BCG-unresponsive NMIBC with CIS (enrollment complete). Cohort 2b (45 enrolled as of Nov 11, 2025); Cohort 3 (36 enrolled). FDA RMAT and Fast Track designations.

Per-asset detail extracted from the 10-Q filed 2026-09-08. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	EG-70 (phase 1)
Lead indication	Superficial Bladder Cancer
Lead phase	Phase 1/2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT04752722	Phase 1/2	Recruiting	Sponsor	enGene, Inc.	—	Superficial Bladder Cancer; Non-muscle Invasive Bladder Cancer With Carcinoma in Situ; Non-muscle Invasive Bladder Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for enGene, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	2,104,986	+2,104,986	0.17%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

ENGN — enGene Therapeutics Inc.